Alpha-fetoprotein level predicts recurrence after transplantation in hepatocellular carcinoma

Medicine (United States)

Volumn 95, Issue 3, 2016, Pages

  Dos Santos Schraiber, Luciana ^a   De Mattos, Angelo Alves ^a   Zanotelli, Maria Lucia ^b   Cantisani, Guido Pio Cracco ^b   De Mello Brandao, Ajacio Bandeira ^b   Marroni, Cludio Augusto ^a   Kiss, Guilhermo ^a   Ernani, Lucas ^a   Dos Santos Marcon, Patricia ^a  

^a Universidade Federal de Ciencias da Saude   (Brazil)

^b Irmandade da Santa Casa de Misericordia de Porto Alegre   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; TUMOR MARKER; BIOLOGICAL MARKER;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CASE STUDY; CELL DIFFERENTIATION; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; LIVER TRANSPLANTATION; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR DIFFERENTIATION; BLOOD; BRAZIL; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; ALPHA-FETOPROTEINS; BIOMARKERS; BRAZIL; CARCINOMA, HEPATOCELLULAR; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84985036753     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002478     Document Type: Article

References (57)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA: Cancer J Clin. 2015;65:87-108
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-1127
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132: 2557-2576
4. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-S50
5. Alexander J, Torbenson M, Wu TT, et al. Non-Alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol. 2013;28:848-854
6. Nader LA, de Mattos AA, Bastos GA. Burden of liver disease in Brazil. Liver Int. 2014;34:844-849
7. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022
8. Biselli M, Conti F, Gramenzi A, et al. A new approach to the use of a-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. Br J Cancer. 2015;112:69-76
9. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699
10. Parfitt JR, Marotta P, Alghamdi M, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl. 2007;13:543-551
11. Xu X, Ke QH, Shao ZX, et al. The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig Dis Sci. 2009;54:385-388
12. Hakeem AR, Young RS, Marangoni G, et al. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35: 987-999
13. Hameed B, Mehta N, Sapisochin G, et al. Alpha-fetoprotein level >1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20:945-951
14. Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010;10:129-137
15. Yaprak O, Akyildiz M, Dayangac M, et al. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2012;11:256-261
16. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer. 1954;7:462-503
17. Zhou L, Rui JA, Ye DX, et al. Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg. 2008;32:1748-1756
18. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-338
19. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430
20. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236
21. Brasil Ministerio da Saude. Portaria n (1.160, de 29.5.2006: Criterios para distribuicao de fgado de doadores cadaveres para transplante. Available at. http://bvsms.saude.gov.br/bvs/saudelegis/gm/2006/prt1160-29-05-2006-comp.html. Accessed May 2013
22. Leung JY, Zhu AX, Gordon FD, et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl. 2004;11:1343-1354
23. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10:534-540
24. Zhou J, Fan J, Wu ZQ, et al. Liver transplantation for patients with hepatocellular carcinoma at the Liver Cancer Institute of Fudan University, China. Chin Med J. 2005;118:654-659
25. Chan KM, Chou HS, Wu TJ, et al. Characterization of hepatocellular carcinoma recurrence after liver transplantation: perioperative prognostic factors, patterns, and outcome. Asian J Surg. 2011;34:128-134
26. Felga G, Evangelista AS, Salvalaggio PR, et al. Hepatocellular carcinoma recurrence among liver transplant recipients within the Milan criteria. Transplant Proc. 2012;44:2459-2461
27. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidencebased management of hepatocellular carcinoma-An updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23:1535-1547
28. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40:225-235
29. Ishizaki Y, Kawasaki S. The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future). J Gastroenterol. 2008;43:18-26
30. Selby R, Kadry Z, Carr B, et al. Liver transplantation for hepatocellular carcinoma. World J Surg. 1995;19:53-58
31. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991;214:221-229
32. Bismuth H, Chiche L, Adam R, et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg. 1993;218:145-151
33. Fortune BE, Umman V, Gilliland T, et al. Liver transplantation for hepatocellular carcinoma: a surgical perspective. J Clin Gastroenterol. 2013;47:S37-S42
34. Freitas AC, Parolin MB, Stadnik L, et al. Hepatocellular carcinoma: impact of waiting list and pre-operative treatment strategies on survival of cadaveric liver transplantation in pre-Model for Endstage Liver Disease era in one center in Brazil. Arq Gastroenterol. 2007;44:189-194
35. de Ataide EC, Garcia M, Mattosinho TJ, et al. Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma. Transplant Proc. 2012;44:2438-2440
36. Hemming AW, Cattral MS, Reed AI, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg. 2001;233:652-659
37. Zimmerman MA, Ghobrial RM, Tong MJ, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg. 2008;143:182-188
38. Ho MC, Wu YM, Hu RH, et al. Liver transplantation for patients with hepatocellular carcinoma. Transplant Proc. 2004;36:2291-2292
39. Kashkoush S, El Moghazy W, Kawahara T, et al. Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria. Clin Transplant. 2014;28:728-736
40. Varona MA, Soriano A, Aguirre-Jaime A, et al. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience. Transplant Proc. 2015;47:84-89
41. Cescon M, Ravaioli M, Grazi GL, et al. Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. J Transplant. 2010;2010:904152
42. Herrero JI, Sangro B, Quiroga J, et al. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl. 2001;7:631-636
43. Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol. 2002;8:193-199
44. Zavaglia C, De Carlis L, Alberti AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol. 2005;100:2708-2716
45. Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg. 2001;136:25-30
46. Shetty K, Timmins K, Brensinger C, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl. 2004;10:911-918
47. Shimoda M, Ghobrial RM, Carmody IC, et al. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with hepatitis C. Liver Transpl. 2004;10:1478-1486
48. Figueras J, Ibanez L, Ramos E, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl. 2001;7:877-883
49. De Carlis L, Giacomoni A, Pirotta V, et al. Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. J Am Coll Surg. 2003;196:887-897
50. Choi HJ, Kim DG, Na GH, et al. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation. World J Gastroenterol. 2013;19:4737-4744
51. Yamashiki N, Gaynor JJ, Kato T, et al. Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma. Am J Transplant. 2004;4:774-781
52. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-1440
53. Cho CS, Knechtle SJ, Heisey DM, et al. Analysis of tumor characteristics and survival in liver transplant recipients with incidentally diagnosed hepatocellular carcinoma. J Gastrointest Surg. 2001;5:594-601
54. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg. 1998;228:479-490
55. Castillo E, Pelletier S, Kumer S, et al. Incidental hepatocellular carcinoma after liver transplantation: population characteristics and outcomes. Transplant Proc. 2009;41:219-221
56. Molmenti EP, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl. 2002;8:736-748
57. Sotiropoulos GC, Malago M, Molmenti EP, et al. Liver transplantation and incidentally found hepatocellular carcinoma in liver explants: need for a new definition? Transplantation. 2006;81: 531-535